The Next Agonist
The middle-ground agonist already exists. You just can't have it.
Here is the fact that reframes the entire Melanotan story: a safe-enough, approved, MC1R-targeted photoprotective drug already made it to market. It’s called afamelanotide, sold as Scenesse — and it is chemically Melanotan I, the original Arizona peptide, developed properly over three decades.
The EU approved it in 2014 and the FDA followed in 2019. It’s a real medicine with real trials behind it. And virtually no one can get it.
Why it’s locked away
Afamelanotide is approved only for erythropoietic protoporphyria (EPP), a rare genetic disorder in which light exposure causes searing pain. For EPP patients the benefit-risk math was clear, the patient population was small and desperate, and the regulatory pathway was tractable. The drug ships as a subcutaneous implant administered in specialty clinics at rare-disease prices.
That’s the pattern worth understanding: the molecule cleared the bar. The indication is what’s narrow. Getting from “treats a rare light-sensitivity disease” to “reduces sun damage for the general fair-skinned public” isn’t a chemistry problem — it’s a trials-economics problem, and a brutal one:
The endpoint is slow and expensive. Proving a drug prevents skin cancer in healthy people means enrolling enormous cohorts and following them for years. Compare that to EPP, where the endpoint — pain-free time in light — shows up in months.
The risk tolerance flips. A drug for healthy people gets held to a far stricter safety standard than a drug for a painful disease with no alternatives. Long-term melanocortin stimulation in millions of healthy users raises questions — including the mole-surveillance question from the gray-market era — that a rare-disease program never had to answer at scale.
The delivery format is wrong for mass adoption. Clinic-administered implants work for a rare disease. A consumer photoprotective would need something closer to a monthly pen or better.
The GLP-1 parallel, taken seriously
The hope animating this site is that photoprotection gets its GLP-1 moment, and the analogy is more structural than it first appears. GLP-1 drugs were peptides confined for years to a “worthy” medical indication (diabetes) while the larger adjacent demand (weight) went unserved or was served by a sketchy supplement-and-gray-market fringe. What broke the dam was a combination the melanocortin field hasn’t yet assembled: outcome trials big enough to satisfy regulators for a broad population, delivery engineering that made self-administration routine, and a commercial thesis that the lifestyle-adjacent market was worth pharmaceutical-scale investment.
Every one of those pieces is conceivable for an MC1R-selective agent. None currently exists. Selectivity chemistry has advanced since MT-II’s shotgun days; sunscreen’s compliance failure is well documented; melanoma incidence gives the public-health case. What’s missing is a sponsor willing to fund the decade-long prevention trial — and possibly an intermediate indication (high-risk patients, transplant recipients, xeroderma-adjacent populations) that could serve as the beachhead the way diabetes did for GLP-1. Who would pay is the file on that invoice.
Labeled hopium
Call this what it is: hope, with a mechanism sketch attached. There is no announced program, as of this writing, racing toward a general-population photoprotective agonist, and readers should treat any product claiming to be that — today, in a vial, from a website — as the cautionary tale section of this site, not this section. The honest position is the uncomfortable one: the science looks feasible, the demand is provably real, and the gap is institutional. Gaps like that do eventually close. GLP-1 proved it. This site is here to watch, and report straight, if this one does.
Common questions
Is there an approved melanocortin drug that protects skin from light?
Yes — afamelanotide, sold as Scenesse, which is chemically the original Melanotan I. The EU approved it in 2014 and the FDA in 2019. But it is approved only for the rare genetic disorder EPP, shipped as a clinic-administered implant at rare-disease prices, so virtually no one else can get it. The molecule cleared the bar; the indication is what's narrow.
Why isn't there a sun-protection drug for the general public?
Not because of chemistry — because of trials economics. Proving a drug prevents skin cancer in healthy people needs enormous cohorts followed for years; the safety bar for dosing well people is far stricter; and a clinic implant is the wrong delivery format for mass use. The gap is institutional, not scientific.